Journal
Blood Advances
Publication Date
3-12-2024
Volume
8
Issue
5
First Page
1116
Last Page
1127
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2023010832
Rights and Permissions
Wistinghausen B, Toner K, Barkauskas DA, Jerkins LP, Kinoshita H, Chansky P, Pezzella G, Saguilig L, Hayashi RJ, Abhyankar H, Scull B, Karri V, Tanna J, Hanley P, Hermiston ML, Allen CE, Bollard CM. Durable immunity to EBV after rituximab and third-party LMP-specific T cells: a Children's Oncology Group study. Blood Adv. 2024 Mar 12;8(5):1116-1127. doi: 10.1182/bloodadvances.2023010832. © 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Recommended Citation
Wistinghausen, Birte; Hayashi, Robert J; and et al., "Durable immunity to EBV after rituximab and third-party LMP-specific T cells: A Children's Oncology Group study." Blood Advances. 8, 5. 1116 - 1127. (2024).
https://digitalcommons.wustl.edu/oa_4/3513
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
